Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru

BACKGROUND: The administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vargas-Herrera, Natalia, Fernández-Navarro, Manuel, Cabezudo, Nestor E., Soto-Becerra, Percy, Solís-Sánchez, Gilmer, Escobar-Agreda, Stefan, Silva-Valencia, Javier, Pampa-Espinoza, Luis, Bado-Pérez, Ricardo, Solari, Lely, Araujo-Castillo, Roger V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576087/
https://www.ncbi.nlm.nih.gov/pubmed/36251630
http://dx.doi.org/10.1371/journal.pone.0268419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576087/
https://www.ncbi.nlm.nih.gov/pubmed/36251630
http://dx.doi.org/10.1371/journal.pone.0268419

Ejemplares similares